Arrowhead Pharmaceuticals to Webcast Fiscal 2024 Second Quarter Results

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that it will host a webcast and conference call on May 9, 2024, at 4:30 p.m. ET to discuss its financial results for the fiscal second quarter ended March

BusinesswireApr 25 04:01

Arrowhead Pharmaceuticals Has Dosed The First Subjects In A Phase 1/2A Trial Of ARO-CFB, The Company's Investigational RNA Interference Therapeutic, In Up To 66 Healthy Volunteers And Patients With Complement Mediated Kidney Disease

Arrowhead Pharmaceuticals Has Dosed The First Subjects In A Phase 1/2A Trial Of ARO-CFB, The Company's Investigational RNA Interference Therapeutic, In Up To 66 Healthy Volunteers And Patients With Co

BenzingaApr 24 19:32

Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) Shares May Have Run Too Fast Too Soon

With a price-to-sales (or "P/S") ratio of 15.2x Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) may be sending bearish signals at the moment, given that almost half of all Biotechs companies in the Unit

Simply Wall StApr 22 23:40

Hepion Ends Phase 2 Study for NASH Drug Due to Cash Restraints

Seeking AlphaApr 20 05:10

Turnstone Biologics Appoints William Waddill to Its Board of Directors

SAN DIEGO, April 16, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. ("Turnstone" or the "Company") (NASDAQ:TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure

GlobeNewswireApr 16 21:00

Wolfe Upgrades Ionis to Outperform, Cites Upcoming Catalysts

Seeking AlphaApr 11 00:03